Updated:
Liquidia Technologies Inc.
Liquidia Technologies is a biopharmaceutical company using PRINT particle engineering to develop YUTREPIA for PAH, approved in 2024.
Liquidia Technologies Inc.
Liquidia Technologies was founded in 2004 by Joseph M. DeSimone and colleagues at the University of North Carolina at Chapel Hill, who developed the PRINT technology to overcome the limitations of traditional drug particle manufacturing (per UNC public records). The company is a publicly traded entity (NASDAQ: LQDA) rather than a private family office, though its ownership includes institutional investors and family-office allocators from prior funding rounds. The underlying wealth origin is not attributed to a single family; Liquidia's capital structure is funded through public equity, private placements, and revenue from product sales. Liquidia's investment is directed entirely toward its pharmaceutical platform: it deploys capital into preclinical research, clinical trials, regulatory filings, and commercial infrastructure for YUTREPIA. In October 2024, the U.S. FDA approved YUTREPIA for the treatment of PAH, a major regulatory milestone that followed a lengthy development path and patent litigation with United Therapeutics (per FDA announcement, October 2024). The company's pipeline also includes a candidate for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and other respiratory conditions. Liquidia does not make external financial investments; instead, its deployment is internal, funding drug development and manufacturing scale-up at its Morrisville and Seattle facilities. Liquidia employs approximately 100–200 people per public filings (per SEC filings, 2024). The team is organized around R&D, clinical operations, regulatory affairs, and commercial functions. The company maintains a single corporate headquarters in Morrisville with a satellite office in Seattle linked to its manufacturing and research activities. There are no disclosed adjacent vehicles such as a philanthropic foundation or operating business separate from the core entity. Liquidia's structural differentiator is its PRINT particle engineering platform, which gives it a unique manufacturing capability for inhaled drug products that competitors cannot easily replicate. Unlike conventional drug manufacturers that rely on milling or spray-drying to create particles, PRINT produces uniform particles with controlled size and shape — potentially improving lung deposition and dosing consistency (per public filings). This platform serves as the moat around Liquidia's pipeline, though the firm has not yet proven blockbuster commercial success beyond YUTREPIA.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Morrisville
Corporate office
Morrisville, NC, United States
Additional offices
Seattle, WA, United States
Sector focus
Frequently asked questions
Who controls investment decisions at Liquidia Technologies?
Liquidia is a publicly traded company (NASDAQ: LQDA) governed by a board of directors and executive management. Investment decisions — including R&D budget allocation and clinical trial funding — are made by the CEO and executive team, subject to board approval. The current CEO is Dr. Roger D. Jeffs or a successor per recent changes; public filings list executive officers. No single-family office controls the firm, though some institutional investors hold significant stakes.
How does Liquidia generate revenue and deploy capital?
Liquidia generates revenue primarily through sales of YUTREPIA, its FDA-approved therapy for PAH. Capital is deployed into R&D for pipeline candidates, clinical trials, manufacturing scale-up, and commercial infrastructure. The company does not make external financial investments or maintain a separate asset-management arm; all deployment is internal to its pharmaceutical operations (per SEC filings).
Is Liquidia a family office or a pharmaceutical company?
Liquidia is a biopharmaceutical company, not a family office. It is structured as a publicly traded corporation (NASDAQ: LQDA) with a drug-development and commercialization mandate. Some family offices may have invested in prior funding rounds, but the firm does not manage third-party capital beyond its public equity structure.
What is the PRINT technology platform?
PRINT (Particle Replication In Non-wetting Templates) is a particle engineering method that produces uniform drug particles with controlled size, shape, and composition. Unlike traditional methods like milling or spray-drying, PRINT allows precise control over particle properties, which can improve lung deposition for inhaled therapies and systemic bioavailability for other delivery routes. The platform is central to Liquidia's pipeline and manufacturing strategy (per UNC and company filings).
What recent regulatory milestones has Liquidia achieved?
In October 2024, the FDA approved YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). This approval followed a years-long development process and ongoing patent litigation with United Therapeutics over competing therapies. The milestone enables Liquidia to commercialize its lead product in the U.S. (per FDA announcement, October 2024).
Which therapeutic areas does Liquidia focus on?
Liquidia's primary focus is on respiratory and cardiovascular diseases. Its lead indication is PAH, and it is pursuing a clinical candidate for chronic thromboembolic pulmonary hypertension (CTEPH). The PRINT platform may enable future expansion into other pulmonary and systemic conditions, though no additional indications have been publicly announced beyond these.
What is Liquidia's relationship with United Therapeutics?
Liquidia and United Therapeutics have engaged in ongoing patent litigation over YUTREPIA versus United's Tyvaso DPI (treprostinil) for PAH. United Therapeutics has alleged patent infringement, while Liquidia has challenged the validity of certain patents. The litigation has influenced YUTREPIA's market launch timing and remains a material risk factor per Liquidia's public filings (per court filings and SEC disclosures).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: